Antiviral resistance and direct-acting antiviral agents for HCV

Antiviral Therapy

Volumn 17, Issue 6 PART B, 2012, Pages 1147-1162

  Aloia, Amanda L ^a   Locarnini, Stephen ^b   Beard, Michael R ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXY 2' FLUORO 2' METHYLCYTIDINE; ABT 333; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BI 207127; BILB 1941; BOCEPREVIR; CILUPREVIR; CYCLOSPORIN A; DACLATASVIR; DANOPREVIR; FALDAPREVIR; FILIBUVIR; GSK 625433; INX 189; INX 198; LOMIBUVIR; MERICITABINE; NARLAPREVIR; NESBUVIR; PEGINTERFERON ALPHA; PYROPHOSPHORIC ACID DERIVATIVE; RG 7277; RIBAVIRIN; SETROBUVIR; SOFOSBUVIR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANIPREVIR; VCH 759; VCH 916;

ANTIVIRAL RESISTANCE; BINDING AFFINITY; BINDING SITE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS GENOME; VIRUS REPLICATION; WILD TYPE;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENOME, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MODELS, MOLECULAR; RNA REPLICASE; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84867253952     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2426     Document Type: Review

References (115)

1. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-107. Medline doi:10.1126/science.282.5386.103
2. Layden TJ, Mika B, Wiley TE. Hepatitis C kinetics: mathematical modeling of viral response to therapy. Semin Liver Dis 2000; 20: 173-183. Medline doi:10.1055/s-2000-9940
3. Nasu A, Marusawa H, Ueda Y, et al. Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing. PLoS ONE 2011; 6: e24907. Medline doi:10.1371/journal.pone.0024907
4. Bartels DJ, Zhou Y, Zhang EZ, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008; 198: 800-807. Medline doi:10.1086/591141
5. Kim AY, Timm J, Nolan BE, et al. Temporal dynamics of a predominant protease inhibitor-resistance mutation in a treatment-naive, hepatitis C virus-infected individual. J Infect Dis 2009; 199: 737-741. Medline doi:10.1086/596657
6. Cubero M, Esteban JI, Otero T, et al. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology 2008; 370: 237-245. Medline doi:10.1016/j.virol.2007.10.006
7. Wang GP, Sherrill-Mix SA, Chang KM, Quince C, Bushman FD. Hepatitis C virus transmission bottlenecks analyzed by deep sequencing. J Virol 2010; 84: 6218-6228. Medline doi:10.1128/JVI.02271-09
8. Verbinnen T, Van Marck H, Vandenbroucke I, et al. Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing. J Virol 2010; 84: 11124-11133. Medline doi:10.1128/JVI.01217-10
9. Bull RA, Luciani F, McElroy K, et al. Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection. PLoS Pathog 2011; 7: e1002243. Medline doi:10.1371/journal.ppat.1002243
10. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008; 48: 1769-1778. Medline doi:10.1002/hep.22549
11. Luber AD. Genetic barriers to resistance and impact on clinical response. J Int AIDS Soc 2005; 7: 69. Medline doi:10.1186/1758-2652-7-3-69
12. Imhof I, Simmonds P. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6. J Virol 2010; 84: 4597-4610. Medline doi:10.1128/JVI.02698-09
13. Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 2011; 141: 1067-1079. Medline doi:10.1053/j.gastro.2011.06.004
14. Le Pogam S, Seshaadri A, Ewing A, et al. RG7128 alone or in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients. J Infect Dis 2010; 202: 1510-1519. Medline doi:10.1086/656774
15. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-1777. Medline doi:10.1053/j. gastro.2007.02.037
16. McCown MF, Rajyaguru S, Kular S, Cammack N, Najera I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009; 53: 2129-2132. Medline doi:10.1128/AAC.01598-08
17. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46: 631-639. Medline doi:10.1002/hep.21781
18. Lim SR, Qin X, Susser S, et al . Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution. Antimicrob Agents Chemother 2012; 56: 271-279. Medline doi:10.1128/AAC.05636-11
19. Ramirez S, Perez-Del-Pulgar S, Carrion JA, et al. Hepatitis C virus compartmentalization and infection recurrence after liver transplantation. Am J Transplant 2009; 9: 1591-1601. Medline doi:10.1111/j.1600-6143.2009.02666.x
20. Sansonno D, Iacobelli AR, Cornacchiulo V, Iodice G, Dammacco F. Detection of hepatitis C virus (HCV) proteins by immunofluorescence and HCV RNA genomic sequences by non-isotopic in situ hybridization in bone marrow and peripheral blood mononuclear cells of chronically HCV-infected patients. Clin Exp Immunol 1996; 103: 414-421. Medline doi:10.1111/j.1365-2249.1996.tb08296.x
21. Cabot B, Martell M, Esteban JI, et al. Nucleotide and amino acid complexity of hepatitis C virus quasispecies in serum and liver. J Virol 2000; 74: 805-811. Medline doi:10.1128/JVI.74.2.805-811.2000
22. Fan X, Solomon H, Poulos JE, Neuschwander-Tetri BA, Di Bisceglie AM. Comparison of genetic heterogeneity of hepatitis C viral RNA in liver tissue and serum. Am J Gastroenterol 1999; 94: 1347-1354. Medline doi:10.1111/j.1572-0241. 1999.01085.x
23. Morikawa K, Lange CM, Gouttenoire J, et al. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus. J Viral Hepat 2011; 18: 305-315. Medline doi:10.1111/j.1365-2893.2011.01451.x
24. Foy E, Li K, Wang C, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300: 1145-1148. Medline doi:10.1126/science.1082604
25. Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 186-189. Medline doi:10.1038/nature02099
26. Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004; 127: 1347-1355. Medline doi:10.1053/j.gastro.2004.08.002
27. Reiser M, Hinrichsen H, Benhamou Y, et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 2005; 41: 832-835. Medline doi:10.1002/hep.20612
28. Lin C, Lin K, Luong YP, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004; 279: 17508-17514. Medline doi:10.1074/jbc.M313020200
29. McCauley JA, McIntyre CJ, Rudd MT, et al. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor. J Med Chem 2010; 53: 2443-2463. Medline doi:10.1021/jm9015526
30. Manns MP, Gane EJ, Rodriguez-Torres M, et al. Sustained viral response (SVR) rates in genotype 1 treatment-naive patients with chronic hepatitis C (CHC) infection treated with vaniprevir (MK-7009), a NS3/4A protease inhibitor, in combination with pegylated interferon alfa-2a and ribavirin for 28 days. Hepatology 2010; 52 Suppl 1: S361A.
31. Gane EJ, Rouzier R, Stedman C, et al. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN alpha-2a/RBV in hepatitis C patients. J Hepatol 2011; 55: 972-979. Medline doi:10.1016/j.jhep.2011.01.046
32. Lagacé L, White PW, Bousquet C, et al. In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335. Antimicrob Agents Chemother 2012; 56: 569-572. Medline doi:10.1128/AAC.05166-11
33. Kukolj G, Benhamou Y, Manns MP, et al. BI 201335, a potent HCV NS3 protease inhibitor, in treatment-naive and experienced chronic HCV genotype-1 infection: genotypic and phenotypic analysis of the NS3 protease domain. J Hepatol 2009; 50 Suppl 1: S347. doi:10.1016/S0168-8278(09)60956-9
34. Lallos LB, McCarville J, Li B, et al. In vitro antiviral activity of IDX320, a novel and potent macrocyclic HCV protease inhibitor. J Hepatol 2010; 52 Suppl 1: S298. doi:10.1016/S0168-8278(10)60770-2
35. Lallos LB, Li B, Soubasakos MA, et al. In vitro resistance and cross-resistance profiles of IDX320, a potent macrocyclic HCV protease inhibitor. (Updated 29 June 2010. Accessed 15 February 2012.) Available from http://idenix.com/hcv/hcv-resistance-workshop-idx320-june-2010-final.pdf
36. Perni RB, Chandorkar G, Chaturvedi PR, et al. VX-950: The discovery of an inhibitor of the hepatitis C NS3-4A protease and a potential hepatitis C virus therapeutic. Hepatology 2003; 38 Suppl 1: S624A. doi:10.1016/S0270-9139(03) 81010-8
37. Reesink H, Forestier N, Weegink CJ, et al . Initial results of a 14-day study of the hepatitis C virus inhibitor protease VX-950, in combination with peginterferon-alpha-2a. J Hepatol 2006; 44 Suppl 2: S272. doi:10.1016/S0168- 8278(06)80737-3
38. Tong X, Bogen S, Chase R, et al. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res 2008; 77: 177-185. Medline doi:10.1016/j.antiviral.2007.11.010
39. Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50: 1709-1718. Medline doi:10.1002/hep.23192
40. Vermehren J, Susser S, Lange CM, et al . Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b. J Viral Hepat 2012; 19: 120-127. Medline doi:10.1111/j.1365-2893.2011.01449.x
41. de Bruijne J, Bergmann JF, Reesink HW, et al. Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients. Hepatology 2010; 52: 1590-1599. Medline doi:10.1002/hep.23899
42. Wong K, Bae A, Qi X, et al. Characterization of HCV resistance from single and multiple dose clinical trials of GS-9256, a novel NS3 protease inhibitor. Hepatology 2010; 52 Suppl 1: S300A.
43. Hagel M, Niu D, St Martin T, et al. AVL-192 potency against HCV NS3 mutants allows for replicon clearance as monotherapy and in combination studies. J Hepatol 2010; 52 Suppl 1: S292. doi:10.1016/S0168-8278(10)60753-2
44. Niu D, Hagel M, Qiao L, et al. AVL-181, a potent and selective irreversible HCV protease inhibitor, exploits the binding site microenvironment to form a targeted and highly specific covalent bond with CYS-159. J Hepatol 2010; 52 Suppl 1: S297. doi:10.1016/S0168-8278(10)60766-0
45. Miyanari Y, Atsuzawa K, Usuda N, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007; 9: 1089-1097. Medline doi:10.1038/ncb1631
46. Masaki T, Suzuki R, Murakami K, et al. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol 2008; 82: 7964-7976. Medline doi:10.1128/JVI.00826-08
47. Tellinghuisen TL, Foss KL, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog 2008; 4: e1000032. Medline doi:10.1371/journal.ppat.1000032
48. Appel N, Zayas M, Miller S, et al. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog 2008; 4: e1000035. Medline doi:10.1371/journal.ppat.1000035
49. Fridell RA, Qiu D, Valera L, Wang C, Rose RE, Gao M. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol 2011; 85: 7312-7320. Medline doi:10.1128/JVI. 00253-11
50. Yang F, Robotham JM, Grise H, et al. A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach. PLoS Pathog 2010; 6: e1001118. Medline doi:10.1371/journal. ppat.1001118
51. Hepatitis C new drug pipeline. (Updated 15 June 2011. Accessed 5 February 2012.) Available from http://hcvdrugs.com/
52. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100. Medline doi:10.1038/nature08960
53. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-224. Medline doi:10.1056/NEJMoa1104430
54. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282-1288. Medline doi:10.1053/jhep.2003.50449
55. Kaul A, Stauffer S, Berger C, et al . Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog 2009; 5: e1000546. Medline doi:10.1371/journal.ppat.1000546
56. Puyang X, Poulin DL, Mathy JE, et al. Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors. Antimicrob Agents Chemother 2010; 54: 1981-1987. Medline doi:10.1128/AAC.01236- 09
57. Behrens SE, Tomei L, De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J 1996; 15: 12-22. Medline (Pubitemid 26020384)
58. Shirota Y, Luo H, Qin W, et al . Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity. J Biol Chem 2002; 277: 11149-11155. Medline doi:10.1074/jbc.M111392200
59. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 1999; 6: 937-943. Medline doi:10.1038/13305
60. Bressanelli S, Tomei L, Roussel A, et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci U S A 1999; 96: 13034-13039. Medline doi:10.1073/pnas.96.23.13034
61. Ago H, Adachi T, Yoshida A, et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure 1999; 7: 1417-1426. Medline doi:10.1016/S0969-2126(00)80031-3
62. Biswal BK, Cherney MM, Wang M, et al. Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors. J Biol Chem 2005; 280: 18202-18210. Medline doi:10.1074/jbc.M413410200
63. McCown MF, Rajyaguru S, Le Pogam S, et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008; 52: 1604-1612. Medline doi:10.1128/AAC.01317-07
64. Ali S, Leveque V, Le Pogam S, et al. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob Agents Chemother 2008; 52: 4356-4369. Medline doi:10.1128/AAC.00444-08
65. Stuyver LJ, McBrayer TR, Tharnish PM, et al. Inhibition of hepatitis C replicon RNA synthesis by beta-D-2′-deoxy-2′-fluoro-2′-C- methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir Chem Chemother 2006; 17: 79-87. Medline
66. Pockros PJ, Jensen DM, Tsai N, et al. First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: interim analysis from the JUMP-C trial. J Hepatol 2011; 54 Suppl 1: S538. doi:10.1016/S0168- 8278(11)61361-5
67. Le Pogam S, Jiang WR, Leveque V, et al. In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 2006; 351: 349-359. Medline doi:10.1016/j.virol.2006. 03.045
68. Nelson DR, Zeuzem S, Andreone P, et al. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Ann Hepatol 2012; 11: 15-31. Medline
69. Lam AM, Murakami E, Espiritu C, et al. PSI-7851, a pronucleotide of beta-D-2′-deoxy-2′-fluoro-2′-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother 2010; 54: 3187-3196. Medline doi:10.1128/AAC.00399- 10
70. Murakami E, Tolstykh T, Bao H, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem 2010; 285: 34337-34347. Medline doi:10.1074/jbc.M110.161802
71. Sofia MJ, Bao D, Chang W, et al. Discovery of a beta-d-2′-deoxy- 2′-alpha-fluoro-2′-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 2010; 53: 7202-7218. Medline doi:10.1021/jm100863x
72. Lawitz E, Rodriguez-Torres M, Denning J, et al. Once daily dual-nucleotide combination of PSI-938 and PSI-7977 provides 94% HCV RNA
73. Gane EJ, Stedman CA, Hyland RH, et al. Once daily PSI-7977 plus RBV: pegylated interferon-alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3. Hepatology 2011; 54 Suppl 1: S377A.
74. Gane E, Stedman C, Anderson J, et al. 100% rapid virologic response for PSI-7977 + ribavirin in genotype 1 null responders (ELECTRON): early viral decline similar to that observed in genotype 1 and genotype 2/3 treatment-naive patients. 19th Conference on Retroviruses and Opportunistic Infections. 5-8 March 2012, Seattle, WA, USA. Abstract 54LB.
75. Kolykhalov A, Liu Y, Bleiman B, Patti J, McGuigan C, Vernachio J. Characterization of in vitro selected hepatitis C virus replicon mutants resistant to the phosphoramidate analog of 2′-c-methylguanosine, INX-189. Hepatology 2010; 52 Suppl 4: S303A.
76. Zhou XJ, Pietropaolo K, Chen J, Khan S, Sullivan-Bolyai J, Mayers D. Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects. Antimicrob Agents Chemother 2011; 55: 76-81. Medline doi:10.1128/AAC.01101-10
77. Kukolj G, McGibbon GA, McKercher G, et al . Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J Biol Chem 2005; 280: 39260-39267. Medline doi:10.1074/jbc.M506407200
78. Erhardt A, Deterding K, Benhamou Y, et al. Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antivir Ther 2009; 14: 23-32. Medline
79. Wang M, Ng KK, Cherney MM, et al. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J Biol Chem 2003; 278: 9489-9495. Medline doi:10.1074/jbc. M209397200
80. Cooper C, Lawitz EJ, Ghali P, et al. Evaluation of VCH-759 monotherapy in hepatitis C infection. J Hepatol 2009; 51: 39-46. Medline doi:10.1016/j.jhep. 2009.03.015
81. Nicolas O, Boivin I, St-Denis C, Bedard J. Genotypic analysis of HCV NS5B variants selected from patients treated with VCH-759. J Hepatol 2008; 48 Suppl 2: S317. doi:10.1016/S0168-8278(08)60846-6
82. Li H, Tatlock J, Linton A, et al. Discovery of (R)-6-cyclopentyl-6-(2-(2, 6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl- [[[[[1,2,4]]]]] triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-on e (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. J Med Chem 2009; 52: 1255-1258. Medline doi:10.1021/jm8014537
83. Shi ST, Herlihy KJ, Graham JP, et al. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2009; 53: 2544-2552. Medline doi:10.1128/AAC.01599-08
84. Love RA, Parge HE, Yu X, et al. Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme. J Virol 2003; 77: 7575-7581. Medline doi:10.1128/JVI.77.13. 7575-7581.2003
85. Troke PJ, Lewis M, Simpson P, et al. Characterization of resistance to the non-nucleoside NS5B inhibitor filibuvir in hepatitis C infected patients. Antimicrob Agents Chemother 2012; 56: 1331-1341. Medline doi:10.1128/AAC.05611- 11
86. Yi G, Deval J, Fan B, et al. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrob Agents Chemother 2012; 56: 830-837. Medline doi:10.1128/AAC.05438-11
87. Rodriguez-Torres M, Lawitz E, Conway B, et al . Safety and antiviral activity of the HCV non-nucleoside polymerase inhibitor VX-222 in treatment naive genotype 1 HCV-infected patients. J Hepatol 2010; 52 Suppl 1: S14. doi:10.1016/S0168-8278(10)60033-5
88. Tomei L, Altamura S, Bartholomew L, et al. Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J Virol 2004; 78: 938-946. Medline doi:10.1128/JVI.78.2.938-946.2004
89. Thompson PA, Patel R, Showalter RE, Li C, Appleman JR, Steffy K. In vitro studies demonstrate that combinations of antiviral agents that include HCV polymerase inhibitor ANA598 have the potential to overcome viral resistance. Hepatology 2008; 48 Suppl 1: S1164A
90. Lawitz E, Rodriguez-Torres M, Rustgi VK, et al. Safety and antiviral activity of ANA598 in combination with pegylated interferon α2A plus ribavirin in treatment-naive genotype-1 chronic HCV patients. J Hepatol 2010; 52 Suppl 1: S467. doi:10.1016/S0168-8278(10)61200-7
91. Lawitz EJ, Rodriguez-Torres M, DeMicco M, et al. Antiviral activity of ANA598, a potent non-nucleoside polymerase inhibitor, in chronic hepatitis C patients. J Hepatol 2009; 50 Suppl 1: S384. doi:10.1016/S0168-8278(09)61057-6
92. Gray F, Amphlett H, Bright L, et al. GSK625433; a novel and highly potent inhibitor of the HCV NS5B polymerase. J Hepatol 2007; 46 Suppl 1: S225. doi:10.1016/S0168-8278(07)62192-8
93. Hang JQ, Yang Y, Harris SF, et al. Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus. J Biol Chem 2009; 284: 15517-15529. Medline doi:10.1074/jbc.M808889200
94. Koev G, Mondal R, Beyer J, et al. Characterization of resistance mutations selected in vitro by the non-nucleoside HCV polymerase inhibitors ABT-333 and ABT-072. J Hepatol 2009; 50 Suppl 1: S346. doi:10.1016/S0168- 8278(09)60955-7
95. Howe AY, Cheng H, Johann S, et al. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Antimicrob Agents Chemother 2008; 52: 3327-3338. Medline doi:10.1128/AAC.00238-08
96. Middleton T, He Y, Beyer J, et al. Resistance profile of ABT-333 and relationship to viral load decrease in patients treated in combination with PEG-interferon and ribavirin for 28 days. J Hepatol 2010; 52 Suppl 1: S296-S297. doi:10.1016/S0168-8278(10)60764-7
97. Shih IH, Vliegen I, Peng B, et al. Mechanistic characterization of GS-9190, a novel non-nucleoside inhibitor of HCV NS5B polymerase with potent antiviral activity and a unique mechanism of action. Hepatology 2007; 46 Suppl 1: S859A.
98. Shih IH, Vliegen I, Peng B, et al . Mechanistic characterization of GS-9190 (tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 2011; 55: 4196-4203. Medline doi:10.1128/AAC.00307-11
99. Bavisotto L, Wang CC, Jacobson IM, et al. Antiviral pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a Phase-1 trial in HCV genotype 1 infected subjects. Hepatology 2007; 46 Suppl 1: S255A.
100. Zeuzem S, Buggisch P, Agarwal K, et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 2012; 55: 749-758. Medline doi:10.1002/hep.24744
101. Summa V, Petrocchi A, Pace P, et al. Discovery of alpha,gamma-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase. J Med Chem 2004; 47: 14-17. Medline doi:10.1021/jm0342109
102. Koch U, Attenni B, Malancona S, et al. 2-(2-Thienyl)-5,6-dihydroxy-4- carboxypyrimidines as inhibitors of the hepatitis C virus NS5B polymerase: discovery, SAR, modeling, and mutagenesis. J Med Chem 2006; 49: 1693-1705. Medline doi:10.1021/jm051064t
103. Powdrill MH, Deval J, Narjes F, De Francesco R, Gotte M. Mechanism of hepatitis C virus RNA polymerase inhibition with dihydroxypyrimidines. Antimicrob Agents Chemother 2010; 54: 977-983. Medline doi:10.1128/AAC.01216-09
104. Tomei L, Altamura S, Paonessa G, De Francesco R, Migliaccio G. HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase. Antivir Chem Chemother 2005; 16: 225-245. Medline (Pubitemid 41139709)
105. Mo H, Ku K, Yang H, et al. Enhanced in vitro antiviral activity and suppression of resistance by combining GS-9256, a novel protease inhibitor, with GS-9190, a non-nucleoside NS5B inhibitor. Hepatology 2010; 52 Suppl 1: S300A.
106. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 1467-1475. Medline doi:10.1016/S0140-6736(10)61384-0
107. Gane E, Pockros PJ, Zeuzem S, et al. Interferon-free treatment with a combination of mericitabine and danoprevir/r with or without ribavirin in treatment-naive HCV genotype 1-infected patients. J Hepatol 2012; 56 Suppl 2: S555. doi:10.1016/S0168-8278 (12)61423-8
108. Zeuzem S, Asselah T, Angus P, et al. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 2011; 141: 2047-2055. Medline doi:10.1053/j.gastro.2011.08.051
109. Larrey D, Lohse A, de Ledinghen V, et al . 4 week therapy with the non-nucleosidic polymerase inhibitor BI207127 in combination with peginterferon-alfa2a and ribavirin in treatment naive and treatment experienced chronic HCV gt1 patients. J Hepatol 2010; 52 Suppl 1: S466. doi:10.1016/S0168- 8278(10)61198-1
110. McPhee F. Identification and preclinical profile of the novel HCV NS3 protease inhibitor BMS-650032. J Hepatol 2010; 52 Suppl 1: S296 doi:10.1016/S0168-8278(10)60763-5
111. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, BMS-790052, and the nonstructural protein 3 protease inhibitor, BMS-650032, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55: 742-748. Medline doi:10.1002/hep.24724
112. Poordad F, Lawitz E, Kowdley K, et al. A 12-week interferon free regimen of ABT-450/r + ABT-333 + ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and 47% of previous non-responders. J Hepatol 2012; 56 Suppl 2: S549. doi:10.1016/S0168-8278(12) 61410-X
113. Folkers GK, Fauci AS. Controlling and ultimately ending the HIV/AIDS pandemic: a feasible goal. JAMA 2010; 304: 350-351. Medline doi:10.1001/jama. 2010.957
114. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293-299. Medline doi:10.1016/S0140-6736(08)61113-7
115. Halfon P, Sarrazin C. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Liver Int 2012; 32: 79-87. Medline doi:10.1111/j.1478-3231.2011.02716.x